AZYO Stock Overview
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets.
Aziyo Biologics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.00|
|52 Week High||US$11.10|
|52 Week Low||US$4.10|
|1 Month Change||11.29%|
|3 Month Change||29.63%|
|1 Year Change||-33.71%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-51.72%|
Recent News & Updates
|AZYO||US Biotechs||US Market|
Return vs Industry: AZYO underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: AZYO underperformed the US Market which returned -18.4% over the past year.
|AZYO Average Weekly Movement||11.1%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: AZYO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: AZYO's weekly volatility (11%) has been stable over the past year.
About the Company
Aziyo Biologics, Inc., a regenerative medicine company, focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. It offers CanGaroo that combines the envelope with antibiotics and is designed to reduce the risk of infection following surgical implantation of an electronic device. The company also provides cardiovascular products, such as ProxiCor for use as an intracardiac patch or pledget for tissue repairs; Tyke for use in neonates and infants to repair pericardial structures; and VasCure, a patch material to repair or reconstruct the peripheral vasculature, including the carotid, renal, iliac, femoral, and tibial blood vessels for cardiovascular, vascular, and general surgeons.
Aziyo Biologics Fundamentals Summary
|AZYO fundamental statistics|
Is AZYO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AZYO income statement (TTM)|
|Cost of Revenue||US$29.03m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.05|
|Net Profit Margin||-60.68%|
How did AZYO perform over the long term?See historical performance and comparison
Is AZYO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AZYO?
Other financial metrics that can be useful for relative valuation.
|What is AZYO's n/a Ratio?|
Price to Sales Ratio vs Peers
How does AZYO's PS Ratio compare to its peers?
|AZYO PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
CRDF Cardiff Oncology
SQZ SQZ Biotechnologies
CADL Candel Therapeutics
SURF Surface Oncology
AZYO Aziyo Biologics
Price-To-Sales vs Peers: AZYO is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (269x).
Price to Earnings Ratio vs Industry
How does AZYO's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: AZYO is good value based on its Price-To-Sales Ratio (2.1x) compared to the US Biotechs industry average (14.1x)
Price to Sales Ratio vs Fair Ratio
What is AZYO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.1x|
|Fair PS Ratio||3.3x|
Price-To-Sales vs Fair Ratio: AZYO is good value based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (3.3x).
Share Price vs Fair Value
What is the Fair Price of AZYO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate AZYO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate AZYO's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AZYO's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Aziyo Biologics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AZYO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AZYO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AZYO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AZYO's revenue (15.6% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: AZYO's revenue (15.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AZYO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Aziyo Biologics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AZYO is currently unprofitable.
Growing Profit Margin: AZYO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AZYO is unprofitable, and losses have increased over the past 5 years at a rate of 26.7% per year.
Accelerating Growth: Unable to compare AZYO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AZYO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: AZYO has a negative Return on Equity (-425.58%), as it is currently unprofitable.
Discover strong past performing companies
How is Aziyo Biologics's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: AZYO's short term assets ($41.1M) exceed its short term liabilities ($27.3M).
Long Term Liabilities: AZYO's short term assets ($41.1M) exceed its long term liabilities ($26.0M).
Debt to Equity History and Analysis
Debt Level: AZYO's net debt to equity ratio (13.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if AZYO's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AZYO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AZYO has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 29.2% each year.
Discover healthy companies
What is Aziyo Biologics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AZYO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AZYO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AZYO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AZYO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as AZYO has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ron Lloyd (60 yo)
Mr. Ronald K. Lloyd, also known as Ron, has been President, Chief Executive Officer and Director of Aziyo Biologics, Inc. from June 2018. Mr. Lloyd served as Executive Vice President and President of Hospi...
CEO Compensation Analysis
Compensation vs Market: Ron's total compensation ($USD1.61M) is above average for companies of similar size in the US market ($USD748.70K).
Compensation vs Earnings: Ron's compensation has been consistent with company performance over the past year.
Experienced Management: AZYO's management team is considered experienced (2.4 years average tenure).
Experienced Board: AZYO's board of directors are considered experienced (5.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.2%.
Aziyo Biologics, Inc.'s employee growth, exchange listings and data sources
- Name: Aziyo Biologics, Inc.
- Ticker: AZYO
- Exchange: NasdaqGM
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$95.341m
- Shares outstanding: 13.62m
- Website: https://www.aziyo.com
Number of Employees
- Aziyo Biologics, Inc.
- 12510 Prosperity Drive
- Suite 370
- Silver Spring
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/28 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.